KRYS Stock Overview
A commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
New Formulations Of VYJUVEK Will Boost Global Market Presence
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$164.83 |
| 52 Week High | US$219.34 |
| 52 Week Low | US$107.50 |
| Beta | 0.80 |
| 1 Month Change | -7.45% |
| 3 Month Change | -10.50% |
| 1 Year Change | 33.11% |
| 3 Year Change | 127.89% |
| 5 Year Change | 174.03% |
| Change since IPO | 1,449.15% |
Recent News & Updates
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing
Dec 18
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07Recent updates
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing
Dec 18Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Shareholder Returns
| KRYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | -3.6% | -2.4% |
| 1Y | 33.1% | -2.7% | 23.3% |
Return vs Industry: KRYS exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: KRYS exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| KRYS volatility | |
|---|---|
| KRYS Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KRYS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRYS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| KRYS fundamental statistics | |
|---|---|
| Market cap | US$4.63b |
| Earnings (TTM) | US$52.37m |
| Revenue (TTM) | US$241.52m |
90.5x
P/E Ratio19.6x
P/S RatioIs KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRYS income statement (TTM) | |
|---|---|
| Revenue | US$241.52m |
| Cost of Revenue | US$17.98m |
| Gross Profit | US$223.54m |
| Other Expenses | US$171.16m |
| Earnings | US$52.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 92.55% |
| Net Profit Margin | 21.68% |
| Debt/Equity Ratio | 0% |
How did KRYS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Krystal Biotech, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |